Taken together, these results suggest that psoralen could inhibit MCF-7 cell proliferation in vivo by inhibiting the β-catenin/Fra-1 signaling pathway; thus, psoralen is a potential therapeutic candidate for breast cancer. This evidence concerns the gene FOSL1 and breast cancer.